Analyst Insights

Alcobra: No Raise Ahead Of Data – Strong Signal To Investors, Says Canaccord

In a research note published yesterday, Canaccord Genuity analyst John Newman reaffirmed a Buy rating on Alcobra (ADHD), and a $40 price target, …

Roth Capital Reiterates Buy On Hecla Mining Following Preliminary 2Q Results

In a research note issued today, Roth Capital analyst Joe Reagor reiterated coverage with a Buy rating on shares of Hecla Mining Company (HL), and a $3.75 price target following preliminary second …

Roth Capital Reiterates Buy On Salesforce.com Following RelateIQ Acquisition

In a research note issued today, Roth Capital analyst Richard Baldry reiterated coverage with a Buy rating on shares of Salesforce.com, Inc (CRM), and an $80 price target on the heels of …

With Peregrine Being A Pivotal Stage Company, We View The Risk/Reward Profile As Favorable, Says Roth Capital

In a research note released today, Roth Capital analyst Joseph Pantginis reiterated coverage with a Buy rating on shares of Peregrine Pharmaceuticals, Inc. (PPHM) and a $5 price target.

Roth Capital Maintains Neutral On Golden Minerals Following Production Restart In Velardena

In a research note released yesterday, Roth Capital analyst Joe Reagor maintained a Neutral rating on Golden Minerals Company (AUMN) with a price …

William Blair Maintaines Outperform On Salix Following Positive FDA Guidance For Relistor Appeal

In a research report issued yesterday, William Blair analyst Tim Lugo maintained an Outperform rating on Salix Pharmaceuticals (SLXP) with a $157 price target, following a …

H.C. Wainwright Initiates Buy On Epizyme; Sees 30% Upside For Stock

In a research note released this morning, H.C.

William Blair Reaffirms Outperform On Abbot Following The Sale Of Generic Drugs Business

In a research note issued yesterday, William Blair analyst Ben Andrew reaffirmed an Outperform rating on Abbott Laboratories (ABT). The report followsyesterday’s news that Abbott will …

William Blair Maintains Market Perform On WisdomTree Ahead Of Q214 Results

In a research note released yesterday, William Blair analyst Christopher Shutler maintained a Market Perform rating on WisdomTree Investments (WETF) amid 2Q14 expectations. No …

William Blair Reiterates Outperform On Riverbed Despite 2Q14 Revenue Miss

In a research note issued yesterday, William Blair analyst Jason Ader reiterated an Outperform rating on Riverbed Technology (RVBD), despite yesterday’s news that RVBD revised its …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts